Literature DB >> 11850109

Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?

Mark A Smith1, Kelly L Drew, Akihiko Nunomura, Atsushi Takeda, Keisuke Hirai, Xiongwei Zhu, Craig S Atwood, Arun K Raina, Catherine A Rottkamp, Lawrence M Sayre, Robert P Friedland, George Perry.   

Abstract

Alzheimer disease (AD) is defined pathologically and diagnostically defined by amyloid-beta senile plaques and neurofibrillary tangles (NFT) composed of tau. From the time of their original description nearly a century ago, a major focus has been to understand the role that these lesions play in the pathogenesis of the disease. The majority favors the notion that these lesions cause the disease and therefore attempts at therapeutic intervention are focused on preventing lesions formation. However, this rationale may be misguided since new evidence from our laboratories and others suggest that the lesions not only occur as a by-product of the fundamental disease process but also that they may be protective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850109     DOI: 10.1016/s0197-0186(01)00123-1

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  27 in total

Review 1.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 2.  The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.

Authors:  Paul S Aisen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Protein misfolding disorders: pathogenesis and intervention.

Authors:  N Gregersen
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

4.  Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype.

Authors:  C Conejero-Goldberg; T M Hyde; S Chen; U Dreses-Werringloer; M M Herman; J E Kleinman; P Davies; T E Goldberg
Journal:  Mol Psychiatry       Date:  2010-05-18       Impact factor: 15.992

Review 5.  Alzheimer's disease pathologic cascades: who comes first, what drives what.

Authors:  Russell H Swerdlow
Journal:  Neurotox Res       Date:  2011-09-13       Impact factor: 3.911

6.  Mitochondrial DNA haplogroups in early-onset Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Johanna Krüger; Reetta Hinttala; Kari Majamaa; Anne M Remes
Journal:  Mol Neurodegener       Date:  2010-02-02       Impact factor: 14.195

Review 7.  Parallels between major depressive disorder and Alzheimer's disease: role of oxidative stress and genetic vulnerability.

Authors:  Roberto Rodrigues; Robert B Petersen; George Perry
Journal:  Cell Mol Neurobiol       Date:  2014-06-14       Impact factor: 5.046

8.  Geniposide Increases Unfolded Protein Response-Mediating HRD1 Expression to Accelerate APP Degradation in Primary Cortical Neurons.

Authors:  Huaqing Cui; Mengsheng Deng; Yonglan Zhang; Fei Yin; Jianhui Liu
Journal:  Neurochem Res       Date:  2018-02-09       Impact factor: 3.996

9.  Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease.

Authors:  Teri L Wadsworth; James A Bishop; Anuradha S Pappu; Randall L Woltjer; Joseph F Quinn
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

Review 10.  APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease.

Authors:  Andrew B Wolf; Richard J Caselli; Eric M Reiman; Jon Valla
Journal:  Neurobiol Aging       Date:  2012-11-16       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.